Shares of Insmed Incorporated (NASDAQ:INSM) have received an average rating of “Buy” from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $36.71.
A number of equities research analysts have recently issued reports on INSM shares. Evercore ISI upped their target price on shares of Insmed from $28.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, September 5th. Leerink Swann upped their price objective on shares of Insmed from $27.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, September 5th. ValuEngine raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Insmed in a report on Wednesday, September 6th. Finally, Robert W. Baird reissued a “positive” rating and issued a $32.00 price objective (up previously from $23.00) on shares of Insmed in a report on Wednesday, September 6th.
In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total value of $487,500.00. Following the completion of the sale, the director now owns 71,131 shares of the company’s stock, valued at $2,311,757.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.10% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in Insmed in the second quarter valued at about $129,000. BNP Paribas Arbitrage SA lifted its position in Insmed by 666.7% in the second quarter. BNP Paribas Arbitrage SA now owns 7,498 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 6,520 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new position in Insmed in the second quarter valued at about $187,000. Virtu KCG Holdings LLC acquired a new position in Insmed in the second quarter valued at about $201,000. Finally, Redmile Group LLC acquired a new position in Insmed in the second quarter valued at about $212,000. 95.28% of the stock is currently owned by institutional investors.
Shares of Insmed (INSM) opened at $31.40 on Friday. Insmed has a 1-year low of $11.49 and a 1-year high of $32.94. The stock has a market cap of $2,400.00, a price-to-earnings ratio of -10.06 and a beta of 1.19. The company has a current ratio of 15.21, a quick ratio of 15.21 and a debt-to-equity ratio of 0.13.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.